Tenet Healthcare Corporation stocks have been trading up by 17.17 percent following highly positive coverage on its improving earnings outlook.
Click Here for a Millionaire's POV on Trading THC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Q2 2026 saw adjusted EPS jump to $6.12 versus $4.26 consensus and $4.02 last year on $5.63B revenue, powered by strong same-store growth, better hospital margins, and ambulatory strength.
- Management lifted 2026 guidance to adjusted EPS of $20.30–$21.69 and revenue of $21.9B–$22.5B, with about $295M more EBITDA and $225M more free cash flow at the midpoint.
- The board expanded the share repurchase authorization by $2.0B after $1.04B in recent buybacks, leaving $2.13B capacity and implying an aggressive roughly 6% buyback at current prices.
- Shares of Tenet Healthcare Corporation jumped more than 17% after the beat-and-raise quarter, as BofA, Barclays, Wells Fargo, UBS, and Guggenheim all backed bullish ratings and mostly higher targets in the $231–$290 band.
- Analysts pointed to Tenet Healthcare Corporation’s standout performance versus peers cutting guidance, citing cost controls, higher-acuity services, and about $140M in incremental Medicaid supplemental payments, while still flagging Medicaid as a key risk.
Weekly Update Jul 20 – Jul 24, 2026: On Saturday, July 25, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 17.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Tenet Healthcare is executing from a position of fundamental strength, with hospital and ambulatory margins well above peer averages. EBIT margin at 18.6% and EBITDA margin at 22.8% are top‑quartile for Healthcare Providers, while ROE near 38–48% and ROIC in the low‑ to mid‑teens signal robust capital efficiency. The stock trades at ~9x earnings and ~2.5x FCF, an undemanding valuation given double‑digit revenue growth, $1.46B quarterly FCF, and accelerating buybacks despite elevated leverage (D/E 2.74).
Technically, THC is in a powerful uptrend following a high‑volume earnings gap. The stock moved from around $196 to $233 in three sessions, with an intraday spike above $230 and very strong closing demand, confirming institutional accumulation in 5‑minute tape and volume. The dominant trend is firmly bullish. The key actionable level is the breakout zone at $220–224: above this, dips are buyable; a sustained break below $220 would signal a failed breakout and justify tighter risk management.
More Breaking News
- Digital Realty Trust Soars After Big Earnings Beat And Guidance Hike
- SSNC Stock Jumps As Earnings Beat, AI Deals Power Breakout
- AMIX Drops As Warrant Inducement Raises Dilution Fears
- Lockheed Martin Stock Jumps As Long-Term Defense Contracts Pile Up
Recent Q2 results and guidance resets firmly separate Tenet from the broader Healthcare Providers & Services group, many of which are cutting outlooks. THC delivered a material beat, raised 2026 EPS and EBITDA guidance, and expanded buybacks by $2B, with over $2.1B still authorized. Multiple bulge‑bracket upgrades and targets in the $230–290 range support multiple expansion from a still‑discounted PE versus high‑quality peers. I see upside toward $270–290 over 12 months, with support at $220 and initial resistance near $250.
Quick Financial Overview
Tenet Healthcare Corporation just delivered the kind of quarter that forces the market to reprice a stock. Q2 adjusted EPS of $6.12 versus $4.26 Street and $4.02 a year ago came with revenue at $5.63B, above expectations. The beat was not only top line; it was also driven by better hospital margins, solid ambulatory surgery performance, and tight expense control. That mix matters for traders because it points to execution, not just one-off gains.
On guidance, Tenet Healthcare Corporation reset the bar higher. Management now sees 2026 adjusted EPS at $20.30–$21.69 and revenue at $21.9B–$22.5B, with about $295M more EBITDA and $225M more free cash flow at the midpoint. Current fundamentals back this stance: trailing revenue is around $21.31B, EBIT margin is 18.6%, and EBITDA margin is 22.8%. Returns on equity are high, with ROE above 37%, and the P/E near 9.2 and price-to-sales around 0.72 suggest the market is still not paying a rich multiple for this growth and profitability profile.
On the chart, THC exploded after the news. Weekly data show the stock basing just under $200 before ripping to an intraday high near $233–$235 and closing the week at $233.20, a clean breakout through prior levels. Intraday, the 5‑minute candle printed a wide range from roughly $229 to almost $247 before settling near $233.20, showing heavy volatility and profit-taking after the gap. For short-term traders, that $229 area now acts as a first support zone, with the $246–$247 region as immediate resistance, while the aggressive buyback and strong free cash flow of about $1.46B provide a fundamental backstop despite leverage (total debt to equity around 2.7).
Conclusion
Tenet Healthcare Corporation is trading like a name that just changed its narrative. A 17%+ spike on the heels of a big earnings beat, higher 2026 guidance, and a larger buyback tells you real money is re-rating the stock. With Q2 EPS well ahead of consensus, strong margins, and free cash flow running above $1.46B, the numbers back the move. The guidance lift and analyst upgrades into the $231–$290 range show that the Street is now modeling a higher earnings base and stronger cash generation.
For traders, the near-term focus is straightforward: can THC hold above the post-gap support zone around the low $230s and build a new base, or does it retrace deeper toward the pre-breakout area near $200? Tenet Healthcare Corporation’s low earnings multiple, high returns, and active buyback argue for dips being bought, but the leverage profile and Medicaid exposure mean pullbacks can be sharp when sentiment cools. This makes it a textbook momentum-and-pullback candidate rather than a set-and-forget holding. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” As I tell my students, “When a stock like THC gaps on real numbers and real guidance, your edge comes from trading the levels and the trend, not from guessing the top.” This is educational analysis only and should be used strictly for research and trading study. “,”scores”:{“risk-level”:”medium”},”trade”:”true
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.